New algorithms for treating homozygous familial... : Current Opinion in Lipidology
ng, but a combination of multiple lipid-lowering therapies (LLT) is key. Patients with (near) absence of LDL receptor expression are most severely affected and frequently require regular lipoprotein apheresis on...
Summary: Hypercholesterolemia is notoriously difficult to control in most patients with HoFH, but multi-LLT, including newer drugs, allows reduction of LDL-C to levels unimaginable until a few years ago. Cost and availability of these new therapies are important future challenges to be addressed.
Share
/>
Relevance: Non–LDLR-dependent therapies approved for lowering LDL cholesterol in patients with HoFH include lomitapide, a microsomal transferase protein inhibitor; evolocumab, an angiopoietin like 3 protein inhibitor; and LDL apheresis. Lomitapide can effectuate dose-dependent LDL cholesterol lowering. In an open-label, single-arm study of...
Share
Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease
Source : https://www.sciencedirect.com/science/article/pii/S2666084922005198?via=ihub
Compound heterozygous familial hypercholesterolemia patients are phenotypically similar to homozygous familial hypercholesterolemia patients, present with significant elevations of low-density lipoprotein cholesterol, and are at risk of cardiovascular disease. Although new...
Conclusions/Relevance: Compound heterozygous familial hypercholesterolemia patients are phenotypically similar to homozygous familial hypercholesterolemia patients, present with significant elevations of low-density lipoprotein cholesterol, and are at risk of cardiovascular disease. Although new treatment options are emerging, the stepwise...
Share
Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575789/
Di Liang, MPhil, a Chang Li, MPhil, a Yanming Tu, MPhil, a Zhiyong Li, Mphil, a and Ming Zhang, MD a, * The additive effects of ezetimibe, evolocumab or alirocumab...
Conclusions: The addition of ezetimibe to statin therapy may further reduce plaque and lipid burdens but may not modify plaque composition. Although current evidence supports a similar impact from the addition of PCSK9 inhibitors to statin therapy, more evidence is needed to confirm such an effect.
Share
-
Lipid Management Connect3yrKey Points • Source: Medicine • Conclusion: “The addition of ezetimibe to statin therapy may further reduce plaque and lipid burdens but may not modify plaque composition. Although current evidence supports a similar Show More
Population genomic screening: Ethical considerations to guide age at implementation
Source : https://www.frontiersin.org/articles/10.3389/fgene.2022.899648/full
Currently, most genetic testing involves next generation sequencing or panel testing, indicating future population-based screening will involve simultaneous testing for multiple disease risks (called here "panel testing"). Genomic screening typically...
Relevance: We conducted an ethical analysis utilizing a hypothetical “narrow” panel test comprised of the CDC Tier 1 Genomic Applications: Familial Hypercholesterolemia (FH), increases individuals’ cardiovascular risk due to elevated low-density lipoprotein (LDL) cholesterol levels; Hereditary Breast and Ovarian Cancer (HBOC), increases...
Share